Tandem Diabetes (TNDM) Tops Q3 EPS by 15c, Updates Guidance

Tandem Diabetes (NASDAQ: TNDM) reported Q3 EPS of ($0.65), $0.15 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $15.7 million versus the consensus estimate of $12.58 million.

Tandem Diabetes sees FY2015 revenue of $70-75 million, versus the consensus of $72.88 million.

• Operating margin is estimated to be in the range of negative 95 percent to negative 105 percent, which includes approximately $13.0 million to $14.0 million in non-cash, stock-based compensation expense.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.

You May Also Be Interested In

• Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold
• Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance